LIXTE Biotechnology Holdings (NASDAQ: LIXT) spent 2025 expanding its presence across multiple segments of oncology innovation. The company is best known for its clinical-stage pharmaceutical pipeline built around LB-100, a first-in-class inhibitor of protein phosphatase 2A (PP2A). Rather than replacing established cancer therapies, LB-100 is designed to enhance their effectiveness. By inhibiting PP2A, the compound stimulates cell-cycle progression and interferes with DNA repair in cancer cells, potentially making tumors more responsive to chemotherapy and immunotherapy.
LB-100 is currently being evaluated in multiple clinical programs targeting solid tumors with significant unmet medical need, including ovarian clear cell carcinoma, metastatic colon cancer, and advanced soft tissue sarcoma. According to extensive published preclinical data available at www.lixte.com, LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer.
LIXTE’s lead compound, LB-100, is part of a pioneering effort in an entirely new field of cancer biology – activation lethality – that is advancing a new treatment paradigm. The company’s new approach is covered by a comprehensive patent portfolio. Proof-of-concept clinical trials are currently in progress for ovarian clear cell carcinoma and metastatic colon cancer.
The latest news and updates relating to LIXT are available in the company’s newsroom at https://ibn.fm/LIXT. For more information about LIXTE Biotechnology Holdings, visit the company’s website.
